Barbiturates are a class of sedative drugs that slow down the central nervous system. First synthesized in 1864, they were once among the most widely prescribed medications in the world, used for everything from anxiety and insomnia to seizure control. Today, they’ve largely been replaced by safer alternatives, but a handful of barbiturates remain in clinical use for specific situations where other drugs fall short.
How Barbiturates Work in the Brain
Your brain has a natural braking system built around a chemical messenger called GABA. When GABA binds to its receptor on a nerve cell, it opens a tiny channel that lets chloride ions flow in, which calms that cell’s electrical activity. Barbiturates amplify this process. They bind to the GABA receptor at a separate site from where GABA itself attaches, and they keep those chloride channels open longer than they normally would. The result is a powerful wave of nervous system suppression: muscles relax, anxiety drops, seizure activity quiets, and at higher doses, consciousness fades.
What makes barbiturates particularly potent, and particularly dangerous, is that at high enough concentrations they can force the chloride channel open on their own, without any GABA present at all. This is a critical distinction from benzodiazepines (drugs like diazepam and lorazepam), which can only enhance GABA’s effects and cannot activate the receptor independently. That built-in ceiling makes benzodiazepines far harder to fatally overdose on. Barbiturates have no such ceiling.
Why They Fell Out of Favor
For most of the early and mid-20th century, barbiturates were the go-to treatment for anxiety, insomnia, and seizures. That changed in the 1960s with the arrival of the first benzodiazepine, chlordiazepoxide. Benzodiazepines offered similar calming effects with a much wider margin of safety. The gap between a therapeutic dose of a barbiturate and a lethal dose is dangerously small, a property pharmacologists call a “narrow therapeutic index.” With barbiturates, doubling or tripling a prescribed dose can suppress breathing to the point of death.
The other major problem is tolerance. With regular use, the body adapts quickly, requiring escalating doses to achieve the same effect. This creates a vicious cycle: the dose that used to work no longer does, but the dose that now “works” sits closer to the lethal threshold. Physical dependence develops alongside tolerance, meaning abrupt cessation triggers withdrawal symptoms that can include life-threatening seizures. Research on patients tapering off phenobarbital found that seizure risk increased sharply once blood levels dropped below a certain threshold, making medically supervised, gradual tapering essential.
Types of Barbiturates
Barbiturates are grouped by how quickly they take effect and how long they last:
- Ultra-short acting: Thiopental and methohexital. These take effect within seconds when given intravenously and wear off in minutes. They were designed for anesthesia induction.
- Short and intermediate acting: Secobarbital, pentobarbital, butalbital, and amobarbital. These take effect within 15 to 40 minutes and last several hours. They were historically prescribed for insomnia and anxiety.
- Long acting: Phenobarbital and primidone. These can remain active in the body for a day or more, making them useful for sustained seizure prevention.
Barbiturates Still Used Today
While most barbiturate prescriptions have been replaced by benzodiazepines or newer medications, several specific uses remain. Phenobarbital is still widely used as an anti-seizure drug in newborns and children. It’s also used in intensive care settings to manage severe alcohol withdrawal. Butalbital, combined with acetaminophen, is approved for tension-type headaches. Primidone treats seizure disorders and essential tremor, a condition that causes involuntary shaking.
In emergency and critical care medicine, barbiturates serve roles that few other drugs can fill. Pentobarbital is used to induce a medically controlled coma in patients with severe traumatic brain injuries when dangerous swelling inside the skull won’t respond to other treatments. In refractory status epilepticus, a condition where seizures continue despite standard treatment, barbiturates like phenobarbital and thiopental can be used to suppress brain activity enough to stop the seizure cycle. Methohexital is still preferred for sedation during electroconvulsive therapy because it allows longer therapeutic seizure duration compared to alternatives.
That said, availability has shifted. The primary supplier of thiopental stopped producing it in 2011, making it essentially unavailable in the United States. Propofol, a non-barbiturate anesthetic, has taken its place for most anesthesia induction.
Legal Classification
In the United States, barbiturates are controlled substances, but their scheduling varies by type. Secobarbital and pentobarbital in their pure forms are Schedule II, the same category as oxycodone, reflecting their high potential for dependence. When these same drugs appear in combination products or suppository forms, they’re classified as Schedule III. Phenobarbital is Schedule IV, the same category as most benzodiazepines, reflecting its somewhat lower abuse potential relative to the shorter-acting barbiturates.
Overdose and Toxicity
The primary danger of barbiturate overdose is respiratory failure. These drugs suppress the brain’s breathing center, and at toxic doses, breathing can slow to the point of stopping entirely. Because tolerance raises the effective dose while the lethal dose stays relatively fixed, people who use barbiturates recreationally or who self-medicate with escalating amounts are at especially high risk. Combining barbiturates with alcohol or other sedatives compounds the danger, since both act on overlapping brain pathways.
Signs of barbiturate toxicity include extreme drowsiness, slurred speech, confusion, dangerously slow breathing, and loss of consciousness. Unlike benzodiazepines, which have a specific reversal agent (flumazenil), there is no antidote that directly counteracts barbiturate effects. Treatment is supportive, focused on maintaining breathing and circulation until the drug clears the body.
Barbiturates vs. Benzodiazepines
Both drug classes enhance GABA activity, but the way they do it creates a fundamental safety difference. Benzodiazepines increase how frequently the chloride channel opens when GABA is present. They make the brain’s natural braking system more efficient, but they can’t activate it alone. Barbiturates increase how long the channel stays open each time, and at high doses, they bypass GABA entirely to force the channel open on their own. This means barbiturate effects can escalate without limit, while benzodiazepine effects plateau once all available GABA receptors are occupied.
This pharmacological difference is why benzodiazepines replaced barbiturates for most purposes starting in the 1960s. For anxiety, insomnia, and routine seizure management, benzodiazepines offer a comparable therapeutic effect with a dramatically lower risk of fatal overdose. Barbiturates persist only in niches where their particular potency is needed, or where decades of clinical experience (as with phenobarbital in neonatal seizures) have established a track record that newer drugs haven’t matched.